JACC. Cardiovascular interventions · 2025
Smoking Status at Baseline and 10-Year Outcomes After Drug-Eluting Stent Implantation: Insights From the DECADE Cooperation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Presch Antonia, Coughlan J J, Bär Sarah, Brugaletta Salvatore, Maeng Michael, Kufner Sebastian, Ortega-Paz Luis, Räber Lorenz, Laugwitz Karl-Ludwig, Jensen Lisette Okkels, Windecker Stephan, Warnakula Olesen Kevin Kris, Sabaté Manel, Heg Dik, Kastrati Adnan, Cassese Salvatore
Аннотация
BACKGROUND: Studies investigating 10-year outcomes according to smoking status at baseline in a largescale population undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation are scarce.
OBJECTIVES: The authors sought to assess the association between smoking status at baseline and 10-year outcomes after PCI with DES implantation.
METHODS: We pooled individual participant data from 5 randomized trials including patients with 10-year follow-up after DES implantation. We divided participants into 2 groups as per smoking status at baseline. The main outcome was all-cause death. Secondary outcomes included cardiovascular death, myocardial infarction (MI), definite stent thrombosis (ST), and repeat revascularization (of target lesion, target vessel [TVR], or non-target vessel).
RESULTS: A total of 9,527 patients undergoing PCI with DES implantation were included in this analysis, (smoking n = 2,365; nonsmoking, n = 7,162). After multivariable adjustment, smoking was associated with a higher risk of all-cause death (HRadj: 1.45; 95% CI: 1.33-1.59), cardiovascular death (HRadj: 1.59; 95% CI: 1.41-1.80), and definite ST (HRadj: 2.09; 95% CI: 1.34-3.26) over 10 years after PCI. The risk of MI was comparable in the first 30 days after PCI, but increased significantly from 1 to 10 years in the smoking group (HRadj: 1.60; 95% CI: 1.36-1.90). Smoking was associated with a lower risk of target lesion revascularization and target vessel revascularization, but a comparable risk of non-target vessel revascularization.
CONCLUSIONS: In patients undergoing PCI with DES, smoking at baseline is associated with an increased risk of death, MI, and ST, but a lower risk of repeat revascularization through to 10 years.
OBJECTIVES: The authors sought to assess the association between smoking status at baseline and 10-year outcomes after PCI with DES implantation.
METHODS: We pooled individual participant data from 5 randomized trials including patients with 10-year follow-up after DES implantation. We divided participants into 2 groups as per smoking status at baseline. The main outcome was all-cause death. Secondary outcomes included cardiovascular death, myocardial infarction (MI), definite stent thrombosis (ST), and repeat revascularization (of target lesion, target vessel [TVR], or non-target vessel).
RESULTS: A total of 9,527 patients undergoing PCI with DES implantation were included in this analysis, (smoking n = 2,365; nonsmoking, n = 7,162). After multivariable adjustment, smoking was associated with a higher risk of all-cause death (HRadj: 1.45; 95% CI: 1.33-1.59), cardiovascular death (HRadj: 1.59; 95% CI: 1.41-1.80), and definite ST (HRadj: 2.09; 95% CI: 1.34-3.26) over 10 years after PCI. The risk of MI was comparable in the first 30 days after PCI, but increased significantly from 1 to 10 years in the smoking group (HRadj: 1.60; 95% CI: 1.36-1.90). Smoking was associated with a lower risk of target lesion revascularization and target vessel revascularization, but a comparable risk of non-target vessel revascularization.
CONCLUSIONS: In patients undergoing PCI with DES, smoking at baseline is associated with an increased risk of death, MI, and ST, but a lower risk of repeat revascularization through to 10 years.